Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Cebranopadol - Grunenthal GmbH

Drug Profile

Cebranopadol - Grunenthal GmbH

Alternative Names: GRT-6005

Latest Information Update: 23 May 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Grunenthal
  • Developer Allergan; Grunenthal
  • Class Cyclohexylamines; Indoles; Opioid analgesics; Small molecules; Spiro compounds
  • Mechanism of Action Nociceptin receptor agonists; Opioid mu receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Back pain; Musculoskeletal pain
  • No development reported Cancer pain; Diabetic neuropathies; Postoperative pain

Most Recent Events

  • 23 May 2019 NCT03958123 - updated only - updated KDM, created HEs
  • 11 Sep 2018 No development reported - Phase-III for Cancer pain in Chile, Romania, Poland, Croatia, Serbia, Bulgaria, Netherlands, Slovakia, Belgium, Sweden, Germany, Denmark, Austria, Hungary, Spain, United Kingdom (PO, Tablet)
  • 10 Sep 2018 No development reported - Phase-II for Diabetic neuropathies in Bulgaria, Romania, Germany (PO, Capsule)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top